The FDA granted orphan-drug status to Alnylam Pharmaceuticals' ALN-AT3 as a treatment for hemophilia A, just a week after receiving the same designation for hemophilia B. ALN-AT3, an injectable RNAi therapeutic designed to treat several rare bleeding diseases, is expected to enter Phase I human studies next year.
Alnylam's RNAi candidate wins orphan designation for hemophilia A
SmartBrief Job Listings for Health Care
|President/Chief Executive Officer||
|Biotechnology/Pharmaceutical Patent Attorney||
Coats and Bennett PLLC
|Director, Payer Marketing||
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
|Chief Medical Officer, Texas Children's Health Plan||
Cejka Executive Search for Texas Childre's Health Plan